The contribution of IL-17 to the development of autoimmunity in psoriasis.
Furue. Masutaka M; Kadono. Takafumi T
Key Findings
- LL-37 is identified as an autoantigen that can activate IL-17‑producing T cells in psoriasis.
- The TNF‑α/IL‑23/IL‑17A axis is central to psoriasis development and responds well to targeted biologic drugs.
- Other auto‑antigens (ADAMTSL5, keratin 17, lipid antigens) also stimulate IL‑17‑driven inflammation.
Practical Outcomes
- If you’re considering LL-37 supplementation or topical use, be aware it might provoke an autoimmune skin response in genetically susceptible individuals. Monitoring for early signs of psoriasis and avoiding high doses of LL-37 could reduce risk. This insight mainly serves as a safety caution rather than a new performance‑boosting protocol.
Summary
The paper explains that psoriasis, a skin disease, is driven by an immune pathway involving IL-17. A natural protein called LL-37, which some people think about using for its antimicrobial benefits, can act as a trigger for this pathway in people with a certain genetic background, potentially worsening or causing psoriasis.
Abstract
Psoriasis is an (auto)immune-mediated disease that manifests as widespread desquamative erythema. The TNF-α/IL-23/IL-17A axis is crucial to its pathogenesis, which is demonstrated by its excellent therapeutic response to biologics that target this axis. There is a strong association between HLA-C*0602 and psoriasis, and researchers have identified autoantigens that are restricted to this major histocompatibility class I molecule. These auto-Ags include LL-37, A disintegrin and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5), and keratin 17. IL-17A-producing T cells have been identified in T cell populations that are reactive to these auto-Ags. In addition, lipid Ags have surfaced as candidate auto-Ags that activate IL-17A-producing T cells in a CD1a-restricted manner. In this article, we review the candidate auto-Ags that may contribute to the activation of the IL-17A-deviated immune response in psoriasis.
Study Information
pubmed
2019
2019-05-24T00:00:00.000Z
10.1177/1753425919852156
23
94